APIM Therapeutics (private company)

APIM Therapeutics is an early stage therapeutic company, pursuing a novel approach for enhancing the efficacy of several currently used cancer therapies on multiple cancer indications. Specifically, APIM Therapeutics focuses on peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), an emerging cancer drug target implicated in the regulation of cellular responses to cellular stress and tumor evasion from therapy.